GSK Stock Jumps 2.8% Pre-Market as First-Line Lung Cancer Drug Jideytro Shows Promising Data

SEOUL — On a stage at the World Conference on Lung Cancer this past Saturday, GlaxoSmithKline presented numbers that could reshape the competitive landscape for a rare but aggressive form of lung cancer. The data, pulled from the registrational Phase I/II ARROS-1 trial, showed that GSK's experimental therapy Jideytro achieved a 15% complete response rate in patients who had not yet received TKI treatment — more than double the rate posted by the closest rival drug on the market.

Shares of GSK (NYSE: GSK) rose 2.8% in pre-market trading on the news. For a company that has long leaned on vaccines and HIV medicines rather than oncology, the results mark an unusually bright entry into a field where first-mover advantages are hard to come by.

A clear lead in a small market

The trial enrolled 94 TKI-naive patients with ROS1-positive non-small cell lung cancer, a subtype that accounts for roughly 1% to 2% of all NSCLC cases. Among those patients, Jideytro produced a 94% objective response rate, with a median follow-up of 15.2 months.

By comparison, Ibtrozi — a ROS1 inhibitor developed by Nuvation Bio — posted complete response rates of just 5% and 7% across two single-arm trials. That gap is what caught analysts' attention: a 15% CR versus 5% to 7% is not a marginal improvement, it is a structural one.

GSK's first shot at oncology revenue

Jideytro is GSK's first commercialized lung cancer drug. If the first-line indication wins regulatory approval, it would place the company directly against established ROS1 inhibitors from Pfizer and Roche in a market that is small by volume but high by price point.

GSK has previously described Jideytro as having "multiple blockbuster-level sales potential." The first-line data released in Seoul gives that claim its strongest evidentiary footing yet.

What remains to be seen is whether regulators will agree. The ARROS-1 trial is registrational, meaning GSK is positioning the data as the basis for a filing. The clock, in other words, starts now.